Sign in
Taking peoplePhase 2

CSX-1004 Effects on Fentanyl-Induced Respiratory Depression

Key facts

Who runs it
Cessation Therapeutics Inc.
Where
Netherlands1 site in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 2
People taking part
24 people, planned
Started
27 Mar 2026
Expected to end
31 May 2027
Type of study
Interventional
Record updated
20 March 2026

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Must provide written informed consent prior to the initiation of any protocol-specific procedures
  • Male and female adults, between 18 and 55 years of age, inclusive
  • Body mass index (BMI) within 18.0 to 32.0 kg/m², inclusive (minimum weight of at least 50.0 kg)
  • Must be medically stable, as determined by medical history, physical examination, ECG, and vital signs at Screening
  • Negative urine drug screen for fentanyl at Screening
  • Is willing and able to comply with the study requirements, including clinic confinement and blood sampling
  • Part B: Diagnosis of mild or moderate opioid use disorder (DSM-5-TR) and self-reported daily opioid use, defined as daily oral MME doses ≥30 to ≤120 mg for at least 3 months

Who cannot take part

  • Requires concomitant treatment with prohibited medications that cannot be safely discontinued prior to first drug administration
  • History or presence of any clinically significant psychiatric, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, renal, or other major disease or illness at Screening
  • Part A: History of or currently meets the criteria for a diagnosis of substance use disorder according to DSM-5-TR criteria for any substances (excluding caffeine)
  • Part B: Currently meets the criteria for a diagnosis of substance use disorder according to DSM-5-TR criteria for any substances, excluding opioids, caffeine, or nicotine
  • Part B: History of or currently meets the criteria for a diagnosis of severe opioid use disorder

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the effect of CSX-1004 Injection on fentanyl-induced respiratory depression in healthy adult participants and participants with OUD, as determined by change in isohypercapnic minute ventilation (MV).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Randomized, Single-Blind, Fixed-Order Crossover Study to Assess the Effects of CSX-1004 Injection on Fentanyl-Induced Respiratory Depression in Healthy Adult Subjects and Subjects with Opioid Use Disorder
Fit questions
Built from 2025-524133-33-00, who can take part
Record updated
20 March 2026